<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cutaneous manifestations of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) may predict disease progression and a poorer prognosis </plain></SENT>
<SENT sid="1" pm="."><plain>We describe a patient in whom a deep <z:e sem="disease" ids="C1142272" disease_type="Disease or Syndrome" abbrv="">neutrophilic dermatosis</z:e> preceded evolution of disease from refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> (refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess blasts) and resolved completely on treating the disease with <z:chebi fb="0" ids="2038">5-azacytidine</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>The dermatological response was accompanied by complete bone marrow remission and trilineage haematological improvement </plain></SENT>
<SENT sid="3" pm="."><plain>We suggest that <z:chebi fb="0" ids="2038">5-azacytidine</z:chebi> should be considered in the treatment of immune mediated cutaneous manifestations of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>